Left Atrial Appendage Implantables
Atrial fibrillation patients are often treated with
oral anticoagulants, which present unwanted
results; however, left atrial fibrillation (LAA)
closure offers an alternative treatment option
to traditional pharmaceuticals.
“LAA closure devices represent a strong
market opportunity for medical device companies,” says Sean Messenger, Millennium
Epicardial LAA closure devices make
minimally invasive procedures possible, with
products such as the Lariat by SentreHeart.
Endocardial LAA closure devices also offer
minimally invasive transcatheter techniques,
such as Boston Scientific’s Watchman, St.
Jude’s Amplatzer, and Coherex Medical’s
Wavecrest. Due to their position inside the
heart, more detailed safety data is available
for endocardial LAA closures, as they have
been required to pass more extensive trials.
Consequently, epicardial devices have received
swifter approval, though their safety has not
been as clinically established.
“As a result, physicians prefer endocardial
LAA closure to epicardial LAA closure, as they
are more familiar with the technology, safety,
and effectiveness,” says Messenger.
Watchman has a great, proven track record
in Europe, as it expects to gain U.S. approval in
2014. While other LAA devices are awaiting FDA
approval, the potential market is expected to reach
over $500 million within the next five years.
Solving Material Safety Concerns
One of the most pressing challenges facing
the advancement of IMDs is that of safety and
security. Aside from issues concerned with the
general biocompatibility of certain materials
used in implantable products, another major
concern relates to infection management.
Anterior Lumbar Interbody Fusion Device: Ante-
rior Lumbar Interbody Fusion Device, construct-
ed of Amedica’s proprietary Si3N4 biomaterial
In the ever growing battle
of healthcare costs, the
industry is seeking new
options to avoid device
malfunctions and infections,
and enhance overall
safety, security, and